Thursday, August 20

Browsing: IDH1Mutant

Support

Safusidenib Earns FDA Fast Track Designation for IDH1-Mutant Glioma

By NewsCancerAugust 20, 20260

The FDA has granted fast track designation to safusidenib, an investigational, oral, brain-penetrant selective inhibitor of mutant IDH1, for the…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.